Prognosis in UC After First Biological

The Long-term Outcome of Patients With Ulcerative Colitis Treated With First Trial of Biological.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05530122

Acronym

biological

Enrollment

192

Registered

2022-09-07

Start date

2009-01-31

Completion date

2022-08-26

Last updated

2022-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative Colitis

Keywords

infliximab, adalimumab, golimumab, ustekinumab, vedolizumab, tofacitinib

Brief summary

To study the long-term clinical outcome of patients with ulcerative colitis treated with first trial of biological therapy.

Detailed description

UC patients treated with at least one biological in Tampere University Hospital between January 2009 and January 2020 were identified and reviewed from patient records.

Interventions

BIOLOGICALinfliximab, adalimumab, golimumab, vedolizumab, ustekinumab

Study design

Observational model

OTHER

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

16 Years to No maximum

Inclusion criteria

* Patients treated for ulcerative colitis for the first trial of biological

Exclusion criteria

* Age under 16 years

Design outcomes

Primary

Measure	Time frame	Description
Response to treatment	within 5 years	Need for colectomy or enhancement of treatment within follow-up
Side-effects	within 5 years	treatment related side-effects reported

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026